Free Trial

Aveanna Healthcare (AVAH) Financials

Aveanna Healthcare logo
$6.84 +0.37 (+5.64%)
As of 02:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Aveanna Healthcare

Annual Income Statements for Aveanna Healthcare

This table shows Aveanna Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2026
Period end date 12/28/2019 1/2/2021 12/31/2022 12/30/2023 12/28/2024 1/3/2026
Net Income / (Loss) Attributable to Common Shareholders
-77 -57 -662 -135 -11 225
Consolidated Net Income / (Loss)
-77 -57 -662 -135 -11 225
Net Income / (Loss) Continuing Operations
-77 -57 -662 -135 -11 225
Total Pre-Tax Income
-75 -52 -664 -139 5.07 107
Total Operating Income
39 -3.49 -642 8.07 140 256
Total Gross Profit
419 455 553 595 636 810
Total Revenue
1,384 1,495 1,788 1,895 2,025 2,433
Operating Revenue
1,384 1,495 1,788 1,895 2,025 2,433
Total Cost of Revenue
965 1,041 1,234 1,300 1,389 1,623
Operating Cost of Revenue
965 1,041 1,234 1,300 1,389 1,623
Total Operating Expenses
380 458 1,196 587 496 554
Selling, General & Admin Expense
228 241 357 361 353 374
Depreciation Expense
14 17 21 14 11 11
Other Operating Expenses / (Income)
116 115 142 107 131 165
Restructuring Charge
23 9.56 0.10 0.47 1.49 3.81
Total Other Income / (Expense), net
-114 -48 -22 -147 -135 -150
Interest Expense
97 83 108 153 157 146
Interest & Investment Income
0.21 0.35 0.68 0.33 0.50 2.83
Other Income / (Expense), net
-17 34 86 5.85 21 -6.40
Income Tax Expense
1.49 5.32 -1.78 -4.47 16 -118
Basic Earnings per Share
($0.56) ($0.40) ($3.57) ($0.71) ($0.06) $1.11
Weighted Average Basic Shares Outstanding
136.91M 140.97M 185.55M 189.96M 192.89M 203.53M
Diluted Earnings per Share
($0.56) ($0.40) ($3.57) ($0.71) ($0.06) $1.05
Weighted Average Diluted Shares Outstanding
136.91M 140.97M 185.55M 189.96M 192.89M 214.98M
Weighted Average Basic & Diluted Shares Outstanding
136.91M 140.97M 185.86M 192.38M 195.09M 217.51M

Quarterly Income Statements for Aveanna Healthcare

This table shows Aveanna Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 4/1/2023 7/1/2023 9/30/2023 12/30/2023 3/30/2024 6/29/2024 9/28/2024 12/28/2024 3/29/2025 6/28/2025 9/27/2025
Net Income / (Loss) Attributable to Common Shareholders
-32 26 -102 -26 -11 14 -43 29 5.19 27 14
Consolidated Net Income / (Loss)
-32 26 -102 -26 -11 14 -43 29 5.19 27 14
Net Income / (Loss) Continuing Operations
-32 26 -102 -26 -11 14 -43 29 5.19 27 14
Total Pre-Tax Income
-30 25 -102 -32 1.49 3.98 -27 27 10 44 13
Total Operating Income
18 37 -76 29 23 37 34 46 52 80 54
Total Gross Profit
144 155 147 148 146 158 160 172 184 211 203
Total Revenue
466 472 478 479 491 505 509 520 559 590 622
Operating Revenue
466 472 478 479 491 505 509 520 559 590 622
Total Cost of Revenue
322 317 331 330 345 347 349 348 376 379 419
Operating Cost of Revenue
322 317 331 330 345 347 349 348 376 379 419
Total Operating Expenses
127 118 224 119 123 121 126 126 132 131 149
Selling, General & Admin Expense
92 91 91 87 88 88 88 89 91 90 95
Depreciation Expense
4.04 3.49 2.96 3.28 2.91 2.83 2.59 2.45 2.59 2.62 2.60
Other Operating Expenses / (Income)
31 23 24 29 32 30 35 33 38 35 52
Restructuring Charge
0.07 -0.03 0.43 - 0.00 0.00 0.15 1.34 0.11 3.40 -1.18
Total Other Income / (Expense), net
-48 -13 -25 -61 -21 -33 -61 -19 -42 -36 -40
Interest Expense
36 38 40 40 40 40 39 38 36 36 41
Interest & Investment Income
0.08 0.11 0.05 0.09 0.10 0.10 0.10 0.20 0.13 0.13 0.83
Other Income / (Expense), net
-12 25 14 -21 18 6.37 -22 19 -5.45 -0.02 -0.00
Income Tax Expense
1.57 -0.81 0.63 -5.86 13 -9.93 16 -2.25 4.96 17 -0.65
Basic Earnings per Share
($0.17) $0.14 ($0.54) ($0.14) ($0.06) $0.07 ($0.22) $0.15 $0.03 $0.13 $0.07
Weighted Average Basic Shares Outstanding
189.05M 189.07M 189.14M 189.96M 192.24M 192.60M 193.36M 192.89M 194.67M 200.97M 208.95M
Diluted Earnings per Share
($0.17) $0.13 ($0.54) ($0.13) ($0.06) $0.07 ($0.22) $0.15 $0.03 $0.13 $0.06
Weighted Average Diluted Shares Outstanding
189.05M 189.74M 189.14M 189.96M 192.24M 196.87M 193.36M 192.89M 206.24M 210.44M 222.23M
Weighted Average Basic & Diluted Shares Outstanding
185.86M 190.43M 190.73M 192.38M 192.38M 193.23M 193.23M 195.09M 195.09M 208.90M 208.91M

Annual Cash Flow Statements for Aveanna Healthcare

This table details how cash moves in and out of Aveanna Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2026
Period end date 12/28/2019 1/2/2021 12/31/2022 12/30/2023 12/28/2024 1/3/2026
Net Change in Cash & Equivalents
-4.67 134 -8.22 25 40 109
Net Cash From Operating Activities
-8.71 117 -48 23 33 126
Net Cash From Continuing Operating Activities
-8.71 117 -48 23 33 126
Net Income / (Loss) Continuing Operations
-77 -57 -662 -135 -11 225
Consolidated Net Income / (Loss)
-77 -57 -662 -135 -11 225
Depreciation Expense
14 17 21 14 11 11
Amortization Expense
6.72 7.53 25 5.18 5.46 5.85
Non-Cash Adjustments To Reconcile Net Income
35 99 609 161 56 80
Changes in Operating Assets and Liabilities, net
12 50 -42 -22 -29 -196
Net Cash From Investing Activities
-18 -194 -25 -8.79 -6.32 -22
Net Cash From Continuing Investing Activities
-18 -194 -25 -8.79 -6.32 -22
Purchase of Property, Plant & Equipment
-17 -15 -12 -6.12 -6.32 -7.45
Acquisitions
-0.96 -178 -2.01 - 0.00 -15
Net Cash From Financing Activities
22 211 62 11 14 5.41
Net Cash From Continuing Financing Activities
22 211 65 11 14 5.41
Repayment of Debt
17 120 -54 -75 -29 -7.38
Issuance of Debt
610 14 115 70 25 0.00
Issuance of Common Equity
0.00 50 4.02 0.95 3.09 6.31
Other Financing Activities, net
-606 29 0.73 15 15 6.48
Cash Interest Paid
93 73 103 138 153 143
Cash Income Taxes Paid
1.55 2.17 1.59 1.14 5.71 31

Quarterly Cash Flow Statements for Aveanna Healthcare

This table details how cash moves in and out of Aveanna Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 4/1/2023 7/1/2023 9/30/2023 12/30/2023 3/30/2024 6/29/2024 9/28/2024 12/28/2024 3/29/2025 6/28/2025 9/27/2025
Net Change in Cash & Equivalents
15 -6.42 20 -4.35 -1.34 5.05 31 5.83 -13 29 45
Net Cash From Operating Activities
7.50 -11 29 -3.01 -12 1.81 29 13 -8.63 52 33
Net Cash From Continuing Operating Activities
7.50 -11 29 -3.01 -12 1.81 29 13 -8.63 52 33
Net Income / (Loss) Continuing Operations
-32 26 -102 -26 -11 14 -43 29 5.19 27 14
Consolidated Net Income / (Loss)
-32 26 -102 -26 -11 14 -43 29 5.19 27 14
Depreciation Expense
4.04 3.49 2.96 3.28 2.91 2.83 2.59 2.45 2.59 2.62 2.60
Amortization Expense
5.66 -2.94 14 -11 1.22 -4.97 1.31 1.66 1.65 1.70 1.49
Non-Cash Adjustments To Reconcile Net Income
21 -5.73 94 51 2.27 18 45 -1.93 27 16 22
Changes in Operating Assets and Liabilities, net
8.75 -31 20 -20 -7.20 -28 24 -18 -45 4.58 -6.86
Net Cash From Investing Activities
-4.80 -1.30 -1.13 -1.57 -1.31 -1.27 -2.21 -1.53 -2.35 -16 -2.02
Net Cash From Continuing Investing Activities
-4.80 -1.30 -1.13 -1.57 -1.31 -1.27 -2.21 -1.53 -2.35 -16 -2.02
Purchase of Property, Plant & Equipment
-2.12 -1.30 -1.13 -1.57 -1.31 -1.27 -2.21 -1.53 -2.35 -1.13 -2.02
Net Cash From Financing Activities
13 5.40 -7.29 0.22 12 4.51 3.62 -6.05 -1.81 -6.34 14
Net Cash From Continuing Financing Activities
13 5.40 -7.29 0.22 12 4.51 3.62 -6.05 -1.81 -6.34 14
Repayment of Debt
-45 -9.23 -11 -9.83 -14 -4.75 -1.06 -9.79 -5.06 -4.74 -1,309
Issuance of Debt
55 10 - 5.00 20 5.00 - - 0.00 - 1,318
Issuance of Common Equity
0.00 0.95 - - 1.35 - 1.74 0.00 1.79 - 2.15
Other Financing Activities, net
3.01 3.68 3.22 5.05 4.28 4.26 2.95 3.74 1.46 -1.61 3.03
Cash Interest Paid
24 36 39 39 38 39 38 38 35 34 44
Cash Income Taxes Paid
-0.39 0.54 0.61 0.37 -0.06 5.00 0.71 0.07 -0.46 16 8.56

Annual Balance Sheets for Aveanna Healthcare

This table presents Aveanna Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2026
Period end date 1/2/2021 1/2/2021 12/31/2022 12/30/2023 12/28/2024 1/3/2026
Total Assets
1,844 1,844 1,712 1,613 1,663 2,012
Total Current Assets
341 341 270 315 393 560
Cash & Equivalents
137 137 19 44 84 193
Accounts Receivable
173 173 221 237 265 313
Prepaid Expenses
11 11 15 16 17 21
Other Current Assets
19 19 14 19 26 33
Plant, Property, & Equipment, net
33 33 23 21 17 17
Total Noncurrent Assets
1,471 1,471 1,419 1,278 1,253 1,435
Noncurrent Note & Lease Receivables
24 24 23 21 22 29
Goodwill
1,316 1,316 1,160 1,055 1,055 1,121
Intangible Assets
74 74 96 94 90 93
Noncurrent Deferred & Refundable Income Taxes
2.93 2.93 - - 0.00 137
Other Noncurrent Operating Assets
54 54 141 108 87 56
Total Liabilities & Shareholders' Equity
1,844 1,844 1,712 1,613 1,663 2,012
Total Liabilities
1,577 1,577 1,716 1,740 1,785 1,817
Total Current Liabilities
260 260 326 355 402 424
Short-Term Debt
13 9.91 9.20 9.20 9.20 13
Accounts Payable
57 57 45 30 36 32
Accrued Expenses
57 57 44 67 88 108
Other Taxes Payable
25 25 0.00 0.00 0.00 0.00
Other Current Liabilities
107 112 229 248 269 271
Total Noncurrent Liabilities
1,319 1,319 1,392 1,388 1,385 1,393
Long-Term Debt
1,163 1,163 1,281 1,276 1,272 1,287
Asset Retirement Reserve & Litigation Obligation
54 54 58 62 67 78
Noncurrent Deferred & Payable Income Tax Liabilities
27 27 3.84 4.86 5.89 0.00
Other Noncurrent Operating Liabilities
73 73 48 45 40 29
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
265 265 -6.31 -130 -124 194
Total Preferred & Common Equity
265 265 -6.31 -130 -124 194
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
265 265 -6.31 -130 -124 194
Common Stock
723 723 1,230 1,242 1,259 1,352
Retained Earnings
-458 -458 -1,237 -1,371 -1,382 -1,157

Quarterly Balance Sheets for Aveanna Healthcare

This table presents Aveanna Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 7/2/2022 10/1/2022 4/1/2023 7/1/2023 9/30/2023 3/30/2024 6/29/2024 9/28/2024 3/29/2025 6/28/2025 9/27/2025
Total Assets
1,909 1,973 1,731 1,741 1,655 1,643 1,664 1,644 1,661 1,771 1,810
Total Current Assets
293 312 308 301 318 336 364 381 408 450 503
Cash & Equivalents
17 64 34 28 48 43 48 78 71 101 146
Accounts Receivable
246 219 242 237 236 258 273 265 295 316 313
Prepaid Expenses
20 13 17 16 12 16 17 12 20 18 14
Other Current Assets
9.99 17 16 20 22 20 27 25 21 15 29
Plant, Property, & Equipment, net
27 25 21 20 22 19 19 18 19 18 17
Total Noncurrent Assets
1,588 1,636 1,401 1,420 1,314 1,287 1,281 1,245 1,234 1,303 1,290
Noncurrent Note & Lease Receivables
23 24 24 27 23 25 24 26 18 21 22
Goodwill
1,367 1,368 1,160 1,160 1,055 1,055 1,055 1,055 1,055 1,119 1,116
Intangible Assets
100 98 98 97 95 93 93 90 89 94 94
Other Noncurrent Operating Assets
97 146 119 136 142 115 110 75 72 69 58
Total Liabilities & Shareholders' Equity
1,909 1,973 1,731 1,741 1,655 1,643 1,664 1,644 1,661 1,771 1,810
Total Liabilities
1,707 1,743 1,765 1,746 1,758 1,777 1,782 1,799 1,759 1,782 1,801
Total Current Liabilities
361 352 376 356 364 382 389 406 388 414 410
Short-Term Debt
8.60 9.20 9.20 9.20 9.20 9.20 9.20 9.20 9.20 9.20 13
Accounts Payable
53 49 43 38 37 43 39 42 30 47 27
Current Employee Benefit Liabilities
- 50 62 - 76 69 73 85 86 - 109
Other Current Liabilities
228 218 262 248 243 261 268 270 263 266 260
Total Noncurrent Liabilities
1,348 1,394 1,391 1,393 1,396 1,397 1,394 1,395 1,373 1,369 1,392
Long-Term Debt
1,239 1,283 1,280 1,279 1,278 1,275 1,274 1,275 1,271 1,269 1,289
Capital Lease Obligations
- 45 43 - 43 39 - 33 29 - 27
Asset Retirement Reserve & Litigation Obligation
60 61 61 64 67 72 24 73 64 63 68
Noncurrent Deferred & Payable Income Tax Liabilities
2.96 2.75 4.44 4.44 4.42 5.47 5.47 5.39 6.51 6.50 6.50
Other Noncurrent Operating Liabilities
46 2.75 2.45 45 4.04 5.94 91 7.31 2.26 29 1.53
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
200 228 -36 -6.74 -106 -136 -119 -156 -100 -12 9.18
Total Preferred & Common Equity
200 228 -36 -6.74 -106 -136 -119 -156 -100 -12 9.18
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
200 228 -36 -6.74 -106 -136 -119 -156 -100 -12 9.18
Common Stock
1,223 1,227 1,233 1,236 1,240 1,246 1,250 1,255 1,277 1,338 1,345
Retained Earnings
-1,023 -999 -1,269 -1,243 -1,345 -1,382 -1,369 -1,411 -1,377 -1,350 -1,336

Annual Metrics And Ratios for Aveanna Healthcare

This table displays calculated financial ratios and metrics derived from Aveanna Healthcare's official financial filings.

Metric 2020 2021 2022 2023 2024 2026
Period end date 12/28/2019 1/2/2021 12/31/2022 12/30/2023 12/28/2024 1/3/2026
DEI Shares Outstanding
- - - - - 208,911,383.00
DEI Adjusted Shares Outstanding
- - - - - 208,911,383.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - 1.08
Growth Metrics
- - - - - -
Profitability Metrics
- - - - - -
Net Operating Profit after Tax (NOPAT)
27 -2.44 -450 5.65 -301 540
Return On Investment Capital (ROIC_SIMPLE)
- - - 0.49% -26.03% 36.11%
Earnings before Interest and Taxes (EBIT)
22 31 -557 14 161 250
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
43 56 -510 33 177 266
Valuation Ratios
- - - - - -
Leverage & Solvency
- - - - - -
Liquidity Ratios
- - - - - -
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 2.83 -413 158 -262 0.00
Efficiency Ratios
- - - - - -
Capital & Investment Metrics
- - - - - -
Invested Capital
1,306 1,301 1,265 1,112 1,073 1,301
Increase / (Decrease) in Invested Capital
0.00 -5.27 -36 -153 -39 0.00
Book Value per Share
$1.94 $1.88 ($0.03) ($0.68) ($0.64) $0.93
Tangible Book Value per Share
($8.22) ($7.98) ($6.79) ($6.70) ($6.56) ($4.88)
Total Capital
1,441 1,438 1,284 1,156 1,157 1,494
Total Debt
1,176 1,173 1,290 1,286 1,281 1,300
Total Long-Term Debt
1,163 1,163 1,281 1,276 1,272 1,287
Net Debt
1,039 1,036 1,271 1,242 1,197 1,107
Capital Expenditures (CapEx)
17 15 12 6.12 6.32 7.45
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-44 -47 -67 -75 -85 -44
Debt-free Net Working Capital (DFNWC)
93 90 -48 -31 -0.30 149
Net Working Capital (NWC)
80 80 -57 -40 -9.50 136
Net Nonoperating Expense (NNE)
104 55 212 140 -290 315
Net Nonoperating Obligations (NNO)
1,041 1,036 1,271 1,242 1,197 1,107
Total Depreciation and Amortization (D&A)
21 25 47 19 16 16
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00 ($0.71) ($0.06) $1.11
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 0.00 189.96M 192.89M 203.53M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 ($0.71) ($0.06) $1.05
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 0.00 189.96M 192.89M 214.98M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 0.00 192.38M 195.09M 217.51M
Normalized Net Operating Profit after Tax (NOPAT)
43 57 23 80 99 182
Debt Service Ratios
- - - - - -
Payout Ratios
- - - - - -

Quarterly Metrics And Ratios for Aveanna Healthcare

This table displays calculated financial ratios and metrics derived from Aveanna Healthcare's official financial filings.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 4/1/2023 7/1/2023 9/30/2023 12/30/2023 3/30/2024 6/29/2024 9/28/2024 12/28/2024 3/29/2025 6/28/2025 9/27/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
3.52% 6.54% 7.90% 6.14% 5.20% 7.00% 6.49% 8.57% 13.98% 16.75% 22.18%
EBITDA Growth
-73.79% 114.25% -165.68% 100.01% 239.32% -34.57% 134.54% 689,300.00% 12.00% 77.20% 267.03%
EBIT Growth
-89.15% 113.88% -224.60% 103.90% 652.80% -30.58% 118.99% 708.37% 12.95% 83.95% 353.57%
NOPAT Growth
-1.18% 112.12% -1,093.85% 114.33% -1,488.55% 235.12% 144.56% 141.82% 115.46% -62.23% 135.83%
Net Income Growth
-226.30% 105.40% -521.39% 89.18% 65.09% -45.68% 58.16% 213.38% 146.48% 94.34% 132.83%
EPS Growth
-221.43% 105.08% -515.38% 89.84% 64.71% -46.15% 59.26% 215.38% 150.00% 85.71% 127.27%
Operating Cash Flow Growth
179.09% 47.10% 35.43% 92.53% -259.73% 117.20% 2.42% 546.12% 27.90% 2,750.69% 12.95%
Free Cash Flow Firm Growth
227.20% 182.80% 1,476.76% 262.22% -108.01% 23.25% -57.20% -48.86% 162.99% -100.17% -145.93%
Invested Capital Growth
-34.49% -12.40% -21.67% -12.08% -9.29% -10.91% -7.87% -3.51% -0.67% 4.43% 10.12%
Revenue Q/Q Growth
3.38% 1.19% 1.29% 0.17% 2.47% 2.92% 0.81% 2.13% 7.57% 5.42% 5.49%
EBITDA Q/Q Growth
107.82% 317.28% -171.97% 100.02% 78.36% -19.54% -62.01% 338.75% -26.62% 66.70% -31.61%
EBIT Q/Q Growth
102.65% 1,049.53% -199.28% 112.89% 411.66% 6.00% -72.84% 448.81% -28.50% 72.62% -33.04%
NOPAT Q/Q Growth
108.63% 213.57% -238.04% 138.37% -936.13% 175.68% -81.64% 108.20% -46.54% 84.86% 14.62%
Net Income Q/Q Growth
86.54% 180.00% -499.97% 74.86% 56.59% 224.47% -408.09% 168.11% -82.20% 420.41% -47.96%
EPS Q/Q Growth
86.72% 176.47% -515.38% 75.93% 53.85% 216.67% -414.29% 168.18% -80.00% 333.33% -53.85%
Operating Cash Flow Q/Q Growth
118.63% -240.33% 372.87% -110.47% -298.40% 115.11% 1,524.88% -54.39% -164.39% 697.42% -35.62%
Free Cash Flow Firm Q/Q Growth
733.69% -68.05% 25.71% -36.26% -131.28% 591.75% -56.34% -23.83% -61.48% -101.31% -11,893.16%
Invested Capital Q/Q Growth
-0.23% -0.69% -6.21% -5.39% 2.93% -2.45% -3.01% -0.91% 5.96% 2.55% 2.27%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
30.97% 32.90% 30.81% 31.00% 29.73% 31.34% 31.37% 33.03% 32.82% 35.76% 32.61%
EBITDA Margin
3.25% 13.39% -9.52% 0.00% 10.48% 8.19% 3.09% 13.26% 9.05% 14.30% 9.27%
Operating Margin
3.78% 7.94% -15.97% 6.12% 4.66% 7.35% 6.68% 8.80% 9.26% 13.58% 8.62%
EBIT Margin
1.17% 13.28% -13.01% 1.67% 8.36% 8.61% 2.32% 12.47% 8.29% 13.57% 8.62%
Profit (Net Income) Margin
-6.86% 5.42% -21.42% -5.37% -2.28% 2.75% -8.42% 5.61% 0.93% 4.58% 2.26%
Tax Burden Percent
105.15% 103.27% 100.62% 81.46% -749.80% 349.48% 156.75% 108.33% 51.17% 61.23% 104.82%
Interest Burden Percent
-558.28% 39.56% 163.57% -393.95% 3.63% 9.15% -231.37% 41.55% 21.89% 55.16% 25.04%
Effective Tax Rate
0.00% -3.27% 0.00% 0.00% 849.80% -249.48% 0.00% -8.33% 48.83% 38.77% -4.82%
Return on Invested Capital (ROIC)
3.00% 11.20% -15.61% 6.83% -55.74% 42.34% 8.22% 17.67% 8.70% 15.86% 18.18%
ROIC Less NNEP Spread (ROIC-NNEP)
-0.47% 10.15% -19.44% 3.15% -43.31% 33.06% 2.93% 16.00% 7.00% 14.04% 14.71%
Return on Net Nonoperating Assets (RNNOA)
-1.92% 130.70% -406.13% -58.22% 648.79% -656.23% -28.17% -154.13% -74.60% -258.73% -241.95%
Return on Equity (ROE)
1.08% 141.90% -421.73% -51.39% 593.05% -613.89% -19.95% -136.45% -65.90% -242.87% -223.77%
Cash Return on Invested Capital (CROIC)
13.64% 5.68% 12.50% 13.33% 10.52% 12.30% 15.84% -24.00% 6.52% 2.05% 6.57%
Operating Return on Assets (OROA)
1.03% 13.33% -13.40% 1.91% 9.52% 9.88% 2.79% 15.41% 10.50% 17.21% 11.42%
Return on Assets (ROA)
-6.03% 5.45% -22.05% -6.13% -2.59% 3.16% -10.12% 6.94% 1.18% 5.81% 3.00%
Return on Common Equity (ROCE)
1.08% 141.90% -421.73% -51.39% 593.05% -613.89% -19.95% -136.45% -65.90% -242.87% -223.77%
Return on Equity Simple (ROE_SIMPLE)
2,005.70% 3,263.77% 327.84% 0.00% 83.43% 105.40% 42.09% 0.00% -5.43% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
12 39 -53 21 -171 130 24 50 27 49 56
NOPAT Margin
2.65% 8.20% -11.18% 4.28% -34.94% 25.70% 4.68% 9.54% 4.74% 8.31% 9.03%
Net Nonoperating Expense Percent (NNEP)
3.47% 1.05% 3.83% 3.68% -12.43% 9.28% 5.29% 1.67% 1.69% 1.82% 3.48%
Return On Investment Capital (ROIC_SIMPLE)
- - - 1.77% - - - 4.28% 2.19% 3.87% 4.20%
Cost of Revenue to Revenue
69.03% 67.10% 69.19% 69.00% 70.27% 68.66% 68.63% 66.97% 67.18% 64.24% 67.39%
SG&A Expenses to Revenue
19.66% 19.34% 19.04% 18.17% 17.92% 17.42% 17.32% 17.07% 16.34% 15.28% 15.34%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
27.19% 24.95% 46.78% 24.88% 25.07% 23.99% 24.69% 24.23% 23.56% 22.18% 24.00%
Earnings before Interest and Taxes (EBIT)
5.45 63 -62 8.02 41 43 12 65 46 80 54
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
15 63 -45 0.01 51 41 16 69 51 84 58
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 199.02
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.11 0.17 0.12 0.27 0.25 0.27 0.50 0.44 0.50 0.45 0.80
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 192.73 52.78 24.22
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.52% 1.89% 4.13%
Enterprise Value to Invested Capital (EV/IC)
1.18 1.26 1.28 1.58 1.54 1.58 2.07 1.95 2.01 1.85 2.53
Enterprise Value to Revenue (EV/Rev)
0.83 0.86 0.81 0.92 0.92 0.90 1.13 1.04 1.09 0.99 1.31
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 53.31 20.59 27.78 17.93 11.82 12.50 9.82 11.51
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 125.89 35.55 58.22 21.45 13.01 13.72 10.63 12.30
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 310.20 189.05 195.12 25.93 0.00 34.20 29.61 16.33
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 77.31 549.10 113.73 137.94 64.25 63.51 25.16 33.63
Enterprise Value to Free Cash Flow (EV/FCFF)
6.86 20.63 9.02 11.07 13.90 12.12 12.52 0.00 30.70 92.12 40.28
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
-37.14 -191.18 -12.58 -9.92 -9.71 -10.79 -8.42 -10.37 -13.07 -106.63 144.72
Long-Term Debt to Equity
-36.89 -189.81 -12.49 -9.85 -9.64 -10.71 -8.36 -10.29 -12.98 -105.86 143.28
Financial Leverage
4.06 12.88 20.89 -18.49 -14.98 -19.85 -9.61 -9.63 -10.65 -18.43 -16.45
Leverage Ratio
6.52 18.87 29.68 -24.47 -19.60 -27.09 -12.58 -12.94 -13.97 -26.23 -23.46
Compound Leverage Factor
-36.39 7.47 48.55 96.39 -0.71 -2.48 29.12 -5.38 -3.06 -14.47 -5.87
Debt to Total Capital
102.77% 100.53% 108.64% 111.21% 111.48% 110.22% 113.47% 110.68% 108.29% 100.95% 99.31%
Short-Term Debt to Total Capital
0.71% 0.72% 0.75% 0.80% 0.77% 0.79% 0.79% 0.80% 0.76% 0.73% 0.99%
Long-Term Debt to Total Capital
102.06% 99.81% 107.89% 110.41% 110.70% 109.43% 112.68% 109.88% 107.52% 100.22% 98.32%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
-2.77% -0.53% -8.64% -11.21% -11.48% -10.22% -13.47% -10.68% -8.29% -0.95% 0.69%
Debt to EBITDA
-2.41 -28.01 -8.27 39.10 15.49 20.18 10.56 7.22 7.16 5.82 5.08
Net Debt to EBITDA
-2.35 -27.40 -7.97 37.76 14.99 19.43 9.93 6.74 6.77 5.36 4.52
Long-Term Debt to EBITDA
-2.39 -27.81 -8.21 38.82 15.38 20.03 10.49 7.17 7.11 5.78 5.03
Debt to NOPAT
-2.98 -12.73 -8.42 227.51 142.17 141.74 15.27 -4.25 19.59 17.55 7.21
Net Debt to NOPAT
-2.90 -12.45 -8.11 219.74 137.59 136.47 14.36 -3.97 18.52 16.17 6.42
Long-Term Debt to NOPAT
-2.96 -12.64 -8.36 225.89 141.18 140.72 15.16 -4.22 19.45 17.42 7.14
Altman Z-Score
0.05 0.24 -0.09 0.15 0.20 0.27 0.34 0.48 0.56 0.67 1.00
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.82 0.85 0.87 0.89 0.88 0.94 0.94 0.98 1.05 1.09 1.23
Quick Ratio
0.74 0.75 0.78 0.79 0.79 0.82 0.85 0.87 0.94 1.01 1.12
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
677 216 272 173 -54 266 116 89 34 -0.45 -53
Operating Cash Flow to CapEx
353.20% -809.70% 2,546.58% -191.65% -915.29% 142.55% 1,328.24% 876.78% -367.63% 4,567.67% 1,644.38%
Free Cash Flow to Firm to Interest Expense
18.82 5.69 6.86 4.36 -1.37 6.73 2.96 2.33 0.94 -0.01 -1.30
Operating Cash Flow to Interest Expense
0.21 -0.28 0.72 -0.08 -0.30 0.05 0.75 0.35 -0.24 1.43 0.81
Operating Cash Flow Less CapEx to Interest Expense
0.15 -0.31 0.70 -0.12 -0.34 0.01 0.69 0.31 -0.30 1.40 0.76
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.88 1.00 1.03 1.14 1.14 1.15 1.20 1.24 1.27 1.27 1.33
Accounts Receivable Turnover
7.47 7.58 8.21 8.28 7.69 7.65 7.92 8.07 7.58 7.39 7.92
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
70.81 77.44 79.61 87.54 93.92 99.94 99.08 106.77 109.19 117.34 129.29
Accounts Payable Turnover
25.04 27.66 30.22 34.77 30.85 34.88 34.96 41.73 38.55 33.88 44.10
Days Sales Outstanding (DSO)
48.85 48.15 44.46 44.08 47.48 47.71 46.11 45.23 48.16 49.38 46.07
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
14.58 13.20 12.08 10.50 11.83 10.46 10.44 8.75 9.47 10.77 8.28
Cash Conversion Cycle (CCC)
34.27 34.95 32.38 33.59 35.65 37.24 35.67 36.48 38.69 38.61 37.80
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
1,262 1,253 1,175 1,112 1,145 1,117 1,083 1,073 1,137 1,166 1,192
Invested Capital Turnover
1.13 1.37 1.40 1.59 1.60 1.65 1.76 1.85 1.83 1.91 2.01
Increase / (Decrease) in Invested Capital
-664 -177 -325 -153 -117 -137 -93 -39 -7.62 49 110
Enterprise Value (EV)
1,491 1,574 1,508 1,753 1,760 1,766 2,238 2,097 2,285 2,157 3,011
Market Capitalization
193 314 227 511 479 531 999 900 1,048 979 1,828
Book Value per Share
($0.19) ($0.04) ($0.56) ($0.68) ($0.71) ($0.62) ($0.81) ($0.64) ($0.51) ($0.06) $0.04
Tangible Book Value per Share
($6.96) ($6.80) ($6.59) ($6.70) ($6.68) ($6.58) ($6.73) ($6.56) ($6.38) ($6.28) ($5.75)
Total Capital
1,296 1,281 1,224 1,156 1,187 1,164 1,161 1,157 1,208 1,267 1,338
Total Debt
1,332 1,288 1,329 1,286 1,323 1,283 1,318 1,281 1,309 1,279 1,329
Total Long-Term Debt
1,323 1,279 1,320 1,276 1,314 1,274 1,309 1,272 1,299 1,269 1,316
Net Debt
1,298 1,260 1,281 1,242 1,281 1,235 1,239 1,197 1,237 1,178 1,183
Capital Expenditures (CapEx)
2.12 1.30 1.13 1.57 1.31 1.27 2.21 1.53 2.35 1.13 2.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-92 -73 -85 -75 -79 -64 -94 -85 -43 -56 -40
Debt-free Net Working Capital (DFNWC)
-58 -45 -37 -31 -37 -16 -15 -0.30 29 45 106
Net Working Capital (NWC)
-67 -54 -46 -40 -46 -25 -25 -9.50 19 36 93
Net Nonoperating Expense (NNE)
44 13 49 46 -160 116 67 20 21 22 42
Net Nonoperating Obligations (NNO)
1,298 1,260 1,281 1,242 1,281 1,235 1,239 1,197 1,237 1,178 1,183
Total Depreciation and Amortization (D&A)
9.70 0.55 17 -8.01 10 -2.14 3.90 4.11 4.24 4.32 4.09
Debt-free, Cash-free Net Working Capital to Revenue
-5.13% -3.99% -4.56% -3.94% -4.13% -3.26% -4.74% -4.18% -2.05% -2.56% -1.73%
Debt-free Net Working Capital to Revenue
-3.22% -2.46% -1.97% -1.62% -1.91% -0.82% -0.78% -0.01% 1.36% 2.06% 4.63%
Net Working Capital to Revenue
-3.73% -2.96% -2.47% -2.10% -2.39% -1.29% -1.24% -0.47% 0.92% 1.64% 4.06%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.17) $0.14 ($0.54) ($0.14) ($0.06) $0.07 ($0.22) $0.15 $0.03 $0.13 $0.07
Adjusted Weighted Average Basic Shares Outstanding
189.05M 189.07M 189.14M 189.96M 192.24M 192.60M 193.36M 192.89M 194.67M 200.97M 208.95M
Adjusted Diluted Earnings per Share
($0.17) $0.13 ($0.54) ($0.13) ($0.06) $0.07 ($0.22) $0.15 $0.03 $0.13 $0.06
Adjusted Weighted Average Diluted Shares Outstanding
189.05M 189.74M 189.14M 189.96M 192.24M 196.87M 193.36M 192.89M 206.24M 210.44M 222.23M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
185.86M 190.43M 190.73M 192.38M 192.38M 193.23M 193.23M 195.09M 195.09M 208.90M 208.91M
Normalized Net Operating Profit after Tax (NOPAT)
12 26 20 21 16 26 24 33 27 51 37
Normalized NOPAT Margin
2.66% 5.56% 4.28% 4.28% 3.26% 5.15% 4.70% 6.34% 4.75% 8.67% 5.90%
Pre Tax Income Margin
-6.52% 5.25% -21.29% -6.60% 0.30% 0.79% -5.37% 5.18% 1.81% 7.49% 2.16%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.15 1.65 -1.57 0.20 1.04 1.10 0.30 1.70 1.28 2.22 1.31
NOPAT to Interest Expense
0.34 1.02 -1.35 0.52 -4.32 3.28 0.61 1.30 0.73 1.36 1.37
EBIT Less CapEx to Interest Expense
0.09 1.62 -1.60 0.16 1.00 1.07 0.24 1.66 1.21 2.19 1.26
NOPAT Less CapEx to Interest Expense
0.28 0.99 -1.38 0.48 -4.36 3.24 0.55 1.26 0.66 1.33 1.32
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Aveanna Healthcare (AVAH) has shown notable revenue growth and improving cash generation over the last few years, but earnings have remained volatile due to one-time items and a high debt load. Below is a concise, data-driven snapshot of trends from AVAH’s quarterly statements in the last four years, focusing on the most recent quarters to provide context for near-term investors.

  • Revenue growth: Quarterly operating revenue rose from the low-to-mid $400s million in 2022 to about $622 million in Q3 2025, marking a meaningful uplift over the four-year window.
  • Net income turning positive in 2025: After multiple years of losses in several quarters, AVAH reported positive net income in Q2 2025 ($27.0 million) and Q3 2025 ($14.1 million), with a string of other recent quarters also showing profitability before other adjustments.
  • Operating cash flow strength: Net cash from continuing operating activities was solid in 2025, notably about $51.6 million in Q2 2025 and $33.2 million in Q3 2025, signaling healthy cash generation from core operations.
  • Free cash flow (approximate) improving: With capex in the low single-digit millions per quarter, near-term free cash flow has been positive in recent 2024–2025 quarters (for example, around $50 million in Q2 2025 and about $31 million in Q3 2025).
  • Margin signals: In Q3 2025, gross margin was around 32–33% (about $203 million gross profit on $622 million revenue), and operating margin approached mid-single digits, indicating improving profitability despite a challenging path earlier in the cycle.
  • Debt management activity: Long-term debt remained high but was actively managed in 2025, with substantial debt issuance offset by large repayments, resulting in a net positive financing cash flow and a net cash increase for the period.
  • Liquidity indicators: Cash & equivalents were meaningful (roughly $146 million in Q3 2025), with total assets around $1.8 billion and total liabilities at a similar scale, suggesting existing liquidity to support near-term needs.
  • Capital-light model: Quarterly capex has been relatively modest (low single-digit millions), supporting a greater share of cash flow remaining available to repay debt or fund growth initiatives.
  • Earnings per share (EPS) improvement: Basic EPS in Q3 2025 was $0.07 and diluted EPS $0.06, reflecting a move toward profitability on a per-share basis in the most recent quarter.
  • One-time and restructuring items: Periods have included non-cash adjustments, impairment charges, and restructuring costs (for example, impairment charges in 2023 and various non-cash and restructuring items across quarters). These items have contributed to earnings volatility but are not ongoing operating cash expenses.
  • Balance sheet dynamics: Total liabilities have been substantial and, in some periods, total equity has been modest or variable due to restatements and large non-cash items. While 2025-Q3 shows a positive near-term net equity position, the path there has included volatility tied to accounting adjustments.
  • Debt load and interest burden: AVAH carries a large debt load (long-term debt in the $1.27–1.29 billion range across 2024–2025) and still incurs meaningful interest expense in quarterly results, which can cap net income during softer revenue periods.
  • Earnings volatility: The company has experienced quarters with negative net income (notably 2023 and 2024), driven by impairment and restructuring costs, which investors should consider when valuing earnings stability.
  • Leveraged funding tailwinds: While debt issuance and repayments indicate active balance-sheet management, the reliance on debt financing and refinancing introduces ongoing financing risk that investors should monitor through future filings.
05/06/26 02:38 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Aveanna Healthcare's Financials

When does Aveanna Healthcare's financial year end?

According to the most recent income statement we have on file, Aveanna Healthcare's fiscal year ends in January. Their fiscal year 2026 ended on January 3, 2026.

How has Aveanna Healthcare's net income changed over the last 5 years?

Aveanna Healthcare's net income appears to be on a downward trend, with a most recent value of $225.03 million in 2026, falling from -$76.52 million in 2020. The previous period was -$10.93 million in 2024. View Aveanna Healthcare's forecast to see where analysts expect Aveanna Healthcare to go next.

What is Aveanna Healthcare's operating income?
Aveanna Healthcare's total operating income in 2026 was $256.46 million, based on the following breakdown:
  • Total Gross Profit: $810.48 million
  • Total Operating Expenses: $554.02 million
How has Aveanna Healthcare's revenue changed over the last 5 years?

Over the last 5 years, Aveanna Healthcare's total revenue changed from $1.38 billion in 2020 to $2.43 billion in 2026, a change of 75.8%.

How much debt does Aveanna Healthcare have?

Aveanna Healthcare's total liabilities were at $1.82 billion at the end of 2026, a 1.8% increase from 2024, and a 15.2% increase since 2020.

How much cash does Aveanna Healthcare have?

In the past 5 years, Aveanna Healthcare's cash and equivalents has ranged from $19.22 million in 2022 to $193.26 million in 2026, and is currently $193.26 million as of their latest financial filing in 2026.

How has Aveanna Healthcare's book value per share changed over the last 5 years?

Over the last 5 years, Aveanna Healthcare's book value per share changed from 1.94 in 2020 to 0.93 in 2026, a change of -51.9%.



Financial statements for NASDAQ:AVAH last updated on 3/23/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners